Document:

EX-10.20

 Exhibit 10.20 

THIRD AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT 

This Third Amendment to Exclusive License Agreement (this “Amendment”) is entered into as of March 25, 2022 (the
“Amendment Date”), by and between Elkurt, Inc., a Rhode Island corporation with an address at 297 President Ave, Providence RI 02906 (“Elkurt”) and Ocean Biomedical Inc., a Delaware corporation with an address at
19W060 Avenue LaTours, Oak Brook, IL 60523 (“Licensee”). 
 WHEREAS, Elkurt and Licensee entered into an Exclusive
License Agreement, subtitled, “BROWN ID 2613 Bispecific (FRG)xAnti-PD-1 (FRGxPD-1)” effective as of July 31, 2020,
as amended by the First Amendment to Exclusive License Agreement effective as of March 21, 2021, and the Second Amendment to Exclusive License Agreement effective as of August 31, 2021 (as so amended, the “License
Agreement”); and 
 WHEREAS, Licensee desires to amend certain terms of the License Agreement, and Elkurt agrees to so amend
the License Agreement, but only upon the terms and conditions set forth in this Amendment. 
 NOW, THEREFORE, Elkurt and Licensee, in
consideration of the foregoing premises and the mutual promises herein, intending to be legally bound, hereby agree as follows: 
 1
Section 1.13 of the License Agreement (the definition of Patent Rights) is hereby amended by replacing the word “Elkurt” with the phrase “Brown or Elkurt.” 

2 Section 4.1. of the License Agreement (regarding Funding) is hereby deleted in its entirety and inserted in place thereof are a
new Section 4.1. as follows: 
 4.1. Funding. Licensee shall raise no less than Ten Million Dollars (US) in equity financing on
or before May 1, 2022. 
 3 Section 10.2.2.4. of the License Agreement (regarding termination if certain fund raising is not
achieved) is hereby amended by deleting the date “April 1, 2022” and inserting in place thereof the date, “May 1, 2022.” 

4 As amended by this Amendment, all provisions of the License Agreement remain in full force and effect and are hereby ratified and
confirmed. All references to the License Agreement, wherever, whenever or however made or contained, are and shall be deemed to be references to the License Agreement as amended by this Amendment. Section 12.6 of the License Agreement
(regarding Governing Law and Jurisdiction) is incorporated herein by reference and made a part hereof and shall govern this Amendment in all respects. This Amendment may be executed in counterparts, each of which shall be deemed to be an original,
and all of which, when taken together, shall constitute one and the same instrument. The signatories may execute this Amendment by electronic means and signatures, copies of which shall each be deemed to be originals. This Amendment constitutes the
entire understanding between the parties hereto with respect to the matters contained herein and this Amendment shall not be modified except in writing executed by all parties hereto. 

[signature page follows] 

  
 1 

 IN WITNESS WHEREOF, the parties hereto execute this Amendment: 

 

					
	Ocean Biomedical, Inc.	  		  	Elkurt, Inc.
			
	By: /s/ Elizabeth
Ng                                        
	  		  	By: /s/ Jonathan Kurtis, MD, PhD                        
	Name: Elizabeth Ng	  		  	Name: Jonathan Kurtis
	Title: Chief Executive Officer	  		  	Title: President

 [Signature Page to Third Amendment to Exclusive License Agreement – BROWN ID 2613]EX-10.23

 Exhibit 10.23 

THIRD AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT 

This Third Amendment to Exclusive License Agreement (this “Amendment”) is entered into as of March 25, 2022 (the
“Amendment Date”), by and between Elkurt, Inc., a Rhode Island corporation with an address at 297 President Ave, Providence RI 02906 (“Elkurt”) and Ocean Biomedical Inc., a Delaware corporation with an address at
19W060 Avenue LaTours, Oak Brook, IL 60523 (“Licensee”). 
 WHEREAS, Elkurt and Licensee entered into an Exclusive
License Agreement, subtitled, “BROWN ID 2613 Bispecific (FRG)xAnti-PD-1 (FRGxPD-1)” effective as of July 31, 2020,
as amended by the First Amendment to Exclusive License Agreement effective as of March 21, 2021, and the Second Amendment to Exclusive License Agreement effective as of August 31, 2021 (as so amended, the “License
Agreement”); and 
 WHEREAS, Licensee desires to amend certain terms of the License Agreement, and Elkurt agrees to so amend
the License Agreement, but only upon the terms and conditions set forth in this Amendment. 
 NOW, THEREFORE, Elkurt and Licensee, in
consideration of the foregoing premises and the mutual promises herein, intending to be legally bound, hereby agree as follows: 
 1
Section 1.13 of the License Agreement (the definition of Patent Rights) is hereby amended by replacing the word “Elkurt” with the phrase “Brown or Elkurt.” 

2 Section 4.1. of the License Agreement (regarding Funding) is hereby deleted in its entirety and inserted in place thereof are a
new Section 4.1. as follows: 
 4.1. Funding. Licensee shall raise no less than Ten Million Dollars (US) in equity financing on
or before May 1, 2022. 
 3 Section 10.2.2.4. of the License Agreement (regarding termination if certain fund raising is not
achieved) is hereby amended by deleting the date “April 1, 2022” and inserting in place thereof the date, “May 1, 2022.” 

4 As amended by this Amendment, all provisions of the License Agreement remain in full force and effect and are hereby ratified and
confirmed. All references to the License Agreement, wherever, whenever or however made or contained, are and shall be deemed to be references to the License Agreement as amended by this Amendment. Section 12.6 of the License Agreement
(regarding Governing Law and Jurisdiction) is incorporated herein by reference and made a part hereof and shall govern this Amendment in all respects. This Amendment may be executed in counterparts, each of which shall be deemed to be an original,
and all of which, when taken together, shall constitute one and the same instrument. The signatories may execute this Amendment by electronic means and signatures, copies of which shall each be deemed to be originals. This Amendment constitutes the
entire understanding between the parties hereto with respect to the matters contained herein and this Amendment shall not be modified except in writing executed by all parties hereto. 

[signature page follows] 

  
 1 

 IN WITNESS WHEREOF, the parties hereto execute this Amendment: 

 

					
	Ocean Biomedical, Inc.	  		  	Elkurt, Inc.
			
	By: /s/ Elizabeth
Ng                                         
                           	  		  	By: /s/ Jonathan Kurtis, MD,
PhD                                        

	Name: Elizabeth Ng	  		  	Name: Jonathan Kurtis
	Title: Chief Executive Officer	  		  	Title: President

 [Signature Page to Third Amendment to Exclusive License Agreement – BROWN ID 2613]EX-10.26

 Exhibit 10.26 

THIRD AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT 

This Third Amendment to Exclusive License Agreement (this “Amendment”) is entered into as of March 25, 2022 (the
“Amendment Date”), by and between Elkurt, Inc., a Rhode Island corporation with an address at 297 President Ave, Providence RI 02906 (“Elkurt”) and Ocean Biomedical Inc., a Delaware corporation with an address at
19W060 Avenue LaTours, Oak Brook, IL 60523 (“Licensee”). 
 WHEREAS, Elkurt and Licensee entered into an Exclusive
License Agreement, subtitled, “BROWN ID 2502 – (Chit1) Small Molecule Antifibrotic” effective as of July 31, 2020, as amended by the First Amendment to Exclusive License Agreement effective as of March 21, 2021, and the
Second Amendment to Exclusive License Agreement effective as of August 31, 2021 (as so amended, the “License Agreement”); and 

WHEREAS, Licensee desires to amend certain terms of the License Agreement, and Elkurt agrees to so amend the License Agreement, but
only upon the terms and conditions set forth in this Amendment. 
 NOW, THEREFORE, Elkurt and Licensee, in consideration of the
foregoing premises and the mutual promises herein, intending to be legally bound, hereby agree as follows: 
 1 Section 1.13 of the
License Agreement (the definition of Patent Rights) is hereby amended by replacing the word “Elkurt” with the phrase “Brown or Elkurt.” 

2 Section 4.1. of the License Agreement (regarding Funding) is hereby deleted in its entirety and inserted in place thereof are a
new Section 4.1. as follows: 
 4.1. Funding. Licensee shall raise no less than Ten Million Dollars (US) in equity financing on
or before May 1, 2022. 
 3 Section 10.2.2.4. of the License Agreement (regarding termination if certain fund raising is not
achieved) is hereby amended by deleting the date “April 1, 2022” and inserting in place thereof the date, “May 1, 2022.” 

4 As amended by this Amendment, all provisions of the License Agreement remain in full force and effect and are hereby ratified and
confirmed. All references to the License Agreement, wherever, whenever or however made or contained, are and shall be deemed to be references to the License Agreement as amended by this Amendment. Section 12.6 of the License Agreement
(regarding Governing Law and Jurisdiction) is incorporated herein by reference and made a part hereof and shall govern this Amendment in all respects. This Amendment may be executed in counterparts, each of which shall be deemed to be an original,
and all of which, when taken together, shall constitute one and the same instrument. The signatories may execute this Amendment by electronic means and signatures, copies of which shall each be deemed to be originals. This Amendment constitutes the
entire understanding between the parties hereto with respect to the matters contained herein and this Amendment shall not be modified except in writing executed by all parties hereto. 

[signature page follows] 

  
 1 

 IN WITNESS WHEREOF, the parties hereto execute this Amendment: 

 

									
	Ocean Biomedical, Inc.	 		 	Elkurt, Inc.
					
	By:	 	 /s/ Elizabeth Ng
	 		 	By:	 	 /s/ Jonathan Kurtis, MD, PhD

	Name: Elizabeth Ng	 		 	Name: Jonathan Kurtis
	Title: Chief Executive Officer	 		 	Title: President

 [Signature Page to Third Amendment to Exclusive License Agreement – BROWN ID 2502]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00343-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00343-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00343-of-00352.parquet"}]]